Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEISH2a ChAd63-KH vaccine study in persistent PKDL
ISRCTN11285604Phase 2Completed
- Sponsor
- University of York
- Start
- Apr 2016
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of ChAd63-KH in leishmaniasis and Post kala-azar dermal leishmaniasis (PKDL) (3 arms), sponsored by University of York. Primary endpoint: Safety. Started Apr 2016; status: completed.
02
Drugs
ChAd63-KH
03
Conditions
leishmaniasisPost kala-azar dermal leishmaniasis (PKDL)
Beyond the preview
Go deeper on ISRCTN11285604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN11285604.